Source page: McKinsey & Company
August 26, 2020
COVID-19 | Pharmaceuticals & Medical Products | Innovation
Work on innovative treatments for severe diseases (such as cancer) has slowed to prevent clinical-trial participants from being exposed to COVID-19.
Work on innovative treatments for severe diseases (such as cancer) has slowed to prevent clinical-trial participants from being exposed to COVID-19. Almost two-thirds of the companies we surveyed expect their development programs to be delayed by more than three months.
Chart family: Scatter Plot · Scatter Plot Customization
To read the article, see “COVID-19 and cell and gene therapy: How to keep innovation on track,” August 18, 2020.
The preview updates when you finish a field or release a slider. Saving only stores this page’s widget settings and spreadsheet data in this browser and does not write back to WordPress.